CTS 1027

Drug Profile

CTS 1027

Alternative Names: CTS-1027

Latest Information Update: 25 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Conatus Pharmaceuticals
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Liver disorders

Most Recent Events

  • 25 Jul 2014 Discontinued - Phase-II for Liver disorders in Puerto Rico (PO)
  • 25 Jul 2014 Discontinued - Phase-II for Liver disorders in USA (PO)
  • 31 Mar 2012 CTS 1027 is no longer licensed to Conatus Pharmaceuticals (Conatus Pharmaceuticals' 2013 Form 10-K filed in March 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top